



Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes[☆]



Teresa Vanessa Fiorentino^{a,b,1}, Adriana Monroy^{b,c,1}, Subash Kamath^{b,1}, Rosa Sotero^a, Michele Dei Cas^d, Giuseppe Daniele^b, Alberto O. Chavez^a, Muhammad Abdul-Ghani^b, Marta Letizia Hribal^a, Giorgio Sesti^e, Devjit Tripathy^b, Ralph A. DeFronzo^b, Franco Folli^{b,f,*}

^a Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy

^b Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States of America

^c Oncology, General Hospital of Mexico, Mexico City, Mexico

^d Clinical Biochemistry and Mass Spectrometry Laboratory, Department of Health Science, University of Milan, Milan, Italy

^e Department of Clinical and Molecular Medicine, University of Rome-Sapienza, Rome, Italy

^f Endocrinology and Metabolism, Department of Health Science, University of Milan, Diabetologia e Malattie Metaboliche, Aziende Socio Sanitarie Territoriali Santi Paolo e Carlo, Milan, Italy

ARTICLE INFO

Article history:

Received 2 August 2020

Accepted 28 October 2020

Keywords:

Mitochondrial proteomics

Type 2 diabetes

Human skeletal muscle biopsies

Mitochondrial dysfunction

Pioglitazone

ABSTRACT

Context: In this study, we aimed to identify the determinants of mitochondrial dysfunction in skeletal muscle (SKLM) of subjects with type 2 diabetes (T2DM), and to evaluate the effect of pioglitazone (PIO) on SKLM mitochondrial proteome.

Methods: Two different groups of adults were studied. Group I consisted of 8 individuals with normal glucose tolerance (NGT) and 8 with T2DM, subjected to SKLM mitochondrial proteome analysis by 2D-gel electrophoresis followed by mass spectrometry-based protein identification. Group II included 24 individuals with NGT and 24 with T2DM, whose SKLM biopsies were subjected to immunoblot analysis. Of the 24 subjects with T2DM, 20 were randomized to receive placebo or PIO (15 mg daily) for 6 months. After 6 months of treatment, SKLM biopsy was repeated.

Results: Mitochondrial proteomic analysis on Group I revealed that several mitochondrial proteins involved in oxidative metabolism were differentially expressed between T2DM and NGT groups, with a downregulation of ATP synthase alpha chain (ATP5A), electron transfer flavoprotein alpha-subunit (ETF A), cytochrome c oxidase subunit VIb isoform 1 (CX6B1), pyruvate dehydrogenase protein X component (ODPX), dihydrolipoamide dehydrogenase (DLDH), dihydrolipoamide-S-succinyltransferase (DLST), and mitofilin, and an up-regulation of hydroxyacyl-CoA-dehydrogenase (HCDH), 3,2-trans-enoyl-CoA-isomerase (D3D2) and delta3,5-delta2,4-dienoyl-CoA-isomerase (ECH1) in T2DM as compared to NGT subjects. By immunoblot analysis on SKLM lysates obtained from Group II we confirmed that, in comparison to NGT subjects, those with T2DM exhibited lower protein levels of ATP5A (−30%, $P = 0.006$), ETF A (−50%, $P = 0.02$), CX6B1 (−30%, $P = 0.03$), key factors for ATP biosynthesis, and of the structural protein mitofilin (−30%, $P = 0.01$). T2DM was associated with a reduced abundance of the enzymes involved in the Krebs cycle DLST and ODPX (−20%, $P \leq 0.05$) and increased levels of HCDH and ECH1, enzymes implicated in the fatty acid catabolism (+30%, $P \leq 0.05$).

In subjects with type 2 diabetes treated with PIO for 6 months we found a restored SKLM protein abundance of ATP5A, ETF A, CX6B1, and mitofilin. Moreover, protein levels of HCDH and ECH1 were reduced by −10% and −15% respectively ($P \leq 0.05$ for both) after PIO treatment.

Conclusion: Type 2 diabetes is associated with reduced levels of mitochondrial proteins involved in oxidative phosphorylation and an increased abundance of enzymes implicated in fatty acid catabolism in SKLM. PIO treatment is able to improve SKLM mitochondrial proteomic profile in subjects with T2DM.

© 2020 Elsevier Inc. All rights reserved.

Abbreviations: ATPA, ATP synthase alpha chain; CX6B1, cytochrome c oxidase subunit VIb isoform 1; DLDH, dihydrolipoamide dehydrogenase; DLST, dihydrolipoamide-S-succinyltransferase; D3D2, 3,2-trans-enoyl-CoA-isomerase; ECH1, delta3,5-delta2,4-dienoyl-CoA-isomerase; ETF A, electron transfer flavoprotein alpha-subunit; HCDH, hydroxyacyl-CoA-dehydrogenase; HDL, high lipoprotein density; IPG, immobilized pH gradient; LDL, low density lipoprotein; NGT, normal glucose tolerance; ODPX, pyruvate dehydrogenase protein X component; PGC-1 α , peroxisome proliferator-activated receptor γ coactivator 1 α ; ROS, reactive oxygen species.

[☆] Trial registration: [Clinical.Trial.gov](https://clinicaltrials.gov) NCT01223196

* Corresponding author at: Endocrinology and Metabolism, Department of Health Science, San Paolo Hospital, Via A. di Rudini' 8, University of Milan, 20143 Milano, Italy.

E-mail address: franco.folli@unimi.it (F. Folli).

¹ Equal first author.

1. Introduction

Insulin resistance in skeletal muscle represents a major etiologic factor in the pathogenesis of type 2 diabetes [1–2]. The mechanisms underlying the impaired insulin responsiveness of insulin target tissues are complex and still incompletely understood. An increasing body of evidence has accumulated indicating a link between mitochondrial dysfunction and insulin resistance [3–6]. In skeletal muscle, mitochondria represent the main source of energy obtained through the enzymatic oxidation of carbohydrates and lipids, and mitochondrial ATP production is essential for the functional and structural integrity of skeletal muscle cells. Cumulative evidence indicates that type 2 diabetes is associated with reduced muscle oxidative capacity and impaired mitochondrial function [4–9], which inhibit insulin signaling through different mechanisms [4,6,10–12]. We and others have shown that disturbances in glucose and fatty acid metabolism result in intracellular accumulation of fatty acid and glycolytic intermediates, which in turn activate molecular pathways such as protein kinase C, nuclear factor κ B, and toll-like receptor 4 networks, known to interfere with insulin signaling [10–16]. Additionally, ATP depletion due to the reduced oxidative phosphorylation has been shown to contribute to insulin resistance by compromising catalytic activity of numerous enzymes involved in insulin signal transduction [17,18]. In addition to energy production, mitochondria are a major source of reactive oxygen species (ROS), and an increased intracellular burden of ROS due to mitochondrial dysfunction is a well-known contributor to insulin resistance in skeletal muscle [11,19–20]. On the other hand, insulin resistance and hyperglycemia may induce mitochondrial dysfunction leading to a negative feedback circle that impairs glucose homeostasis [11,21].

Previous microarray studies designed to examine gene expression abnormalities in skeletal muscle in type 2 diabetic patients have revealed a pattern of reduced expression of genes involved in mitochondrial function [22–24]. However, changes in mRNA levels may not be mirrored by changes in protein abundance. This limitation of these studies supports the need of concomitant proteomic profile analyses. Utilizing proteomic approaches, a number of abnormalities in the skeletal muscle proteome of type 2 diabetic subjects have been described, including a reduced abundance of several mitochondrial proteins involved in oxidative metabolism [25–28]. However, these studies were carried out in a small number of individuals and their findings require confirmation in a larger population.

The thiazolidinedione pioglitazone is an anti-diabetic agent able to improve insulin sensitivity and glycemic control through a variety of molecular mechanisms which have been only partially elucidated [29–31]. Evidence suggests that pioglitazone promotes the expression of peroxisome proliferator-activated receptor γ coactivator 1 α (PGC-1 α), a master modulator of mitochondrial biogenesis and function, thereby, improving mitochondrial oxidative metabolism [30,32–34].

In this study, we aimed to identify the determinants of mitochondrial dysfunction in skeletal muscle of subjects with type 2 diabetes by comparing the skeletal muscle mitochondrial proteomic profile of individuals with type 2 diabetes with that of subjects with normal glucose tolerance (NGT). Moreover, since pioglitazone treatment has been shown to improve mitochondrial function, we evaluated whether pioglitazone can modulate the mitochondrial proteomic pattern in the skeletal muscle of type 2 diabetic subjects.

2. Materials and methods

2.1. Subjects

Two groups of adult individuals were studied at the Bartter Clinical Research Unit (BRU) of the South Texas Veterans Healthcare System, University of Texas Health Science Center at San Antonio. Group I consisted of 8 individuals with NGT and 8 with type 2 diabetes. Following an overnight fasting, subjects underwent to a vastus lateralis muscle

biopsy, and analysis of the skeletal muscle mitochondrial proteome by 2D-gel electrophoresis followed by mass spectrometry-based protein identification was performed on subcellular protein lysates. Group II consisted of 24 individuals with NGT and 24 with type 2 diabetes. After an overnight fasting, they were subjected to a vastus lateralis muscle biopsy, followed by immunoblot analysis of total protein lysates. Of the 24 subjects affected by type 2 diabetes, 20 were randomized to receive placebo ($n = 9$) or pioglitazone (15 mg daily, $n = 11$) for 6 months. After 6 months of treatment, the vastus lateralis muscle biopsy was repeated as described in a previously published study [29].

Inclusion criteria included age = 18–70 years; BMI = 24–40 kg/m², and males/females in equal distribution. All control subjects had a normal OGTT. Other than antidiabetic medications (metformin and/or sulfonylureas), no subjects were taking any medications known to affect glucose metabolism. Statin and antihypertensive therapy was allowed if the dose was stable for at least 4 months. Body weight was stable (± 3 pounds over the preceding 3 months) and no subject participated in excessively heavy exercise programs (≥ 30 min/day, ≥ 3 days/week, walking) [35]. Diabetic subjects taking insulin, thiazolidinediones, glucagon like peptide 1 analogues or dipeptidyl peptidase-IV inhibitors were excluded from the study.

2.2. Experimental design

Following a ~10-h overnight fast, all subjects had a 75 g OGTT with measurement of plasma glucose and insulin concentrations at –30, –15, 0, 30, 60, 90 and 120 min.

On a separate day, following an ~10-h overnight fast subjects underwent to a four-hour euglycemic hyperinsulinemic clamp (80 mU/m²·min) as previously described [29,32]. Briefly, a priming dose of insulin (Humulin, Eli Lilly & Co., Indianapolis, IN) was administered during the initial 10 min to acutely raise the plasma insulin concentration followed by a continuous insulin infusion at 80 mU/m²·min. In diabetic participants, plasma glucose was allowed to decline to 100 mg/dl at which it was maintained by a variable infusion of 20% glucose. Sixty minutes prior to the start of the insulin clamp a percutaneous needle biopsy of the vastus lateralis muscle was performed in all study participants under local anaesthesia using a Bergström needle and the muscle specimens were immediately frozen in liquid nitrogen and stored at –80 °C until analyzed. A second euglycemic hyperinsulinemic clamp and percutaneous needle biopsy of the vastus lateralis muscle was performed in 20 type 2 diabetic patients 6 months after treatment with pioglitazone ($n = 11$) or placebo ($n = 9$).

The study protocol was approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio. Written informed consent was obtained from all study participants in accordance with the guidelines of the Declaration of Helsinki.

2.3. Biochemical analyses

Plasma total and high lipoprotein density (HDL) cholesterol, triglycerides and glucose levels were measured by enzymatic method (GM9, Analox Instruments Ltd., UK). Plasma insulin concentration was measured by radioimmunoassay (Diagnostic Products Corporation, Los Angeles, CA).

2.4. Proteomic analysis

2.4.1. Sample preparation and subcellular fractionation

Subcellular fractionation was performed on skeletal muscle biopsies obtained from subjects in Group I using differential centrifugation to obtain mitochondrial enriched lysates as previously described [36–38]. The entire procedure was performed at 4 °C using buffers containing protease and phosphatase inhibitors (Pierce, Rockford, IL, USA). Specifically, 25 mg of skeletal muscle tissue was homogenized in a homogenization buffer (210 mM mannitol, 70 mM sucrose, 10 mM Tris-HCl pH

7.5, 10 mM EDTA) using a Dounce homogenizer. The homogenate was centrifuged at 800 rpm for 10 min at 4 °C. To improve mitochondrial enrichment from the muscle lysates, the pellet containing unbroken cells was re-homogenized and centrifuged at 800 rpm for 10 min at 4 °C. Supernatants were combined and centrifuged at 10,000 rpm for 10 min. The pellet was washed for 15 min in homogenization buffer for a total of 2 times. This pellet, resuspended in the homogenization buffer, represented the mitochondrial enriched fraction.

2.4.2. Two-dimensional gel electrophoresis

Mitochondrial enriched fractions were re-solubilized in a solution containing 8 M urea, 50 mM DTT, 2% (w/v) CHAPS, 0.2% (w/v) carrier ampholytes and 0.001% (w/v) bromophenol blue. Protein concentration was measured in this solution using the EZQ protein quantitation kit (Invitrogen, Carlsbad, CA, USA). An 11 cm linear immobilized pH gradient (IPG) ReadyStrip (pH 3–10) (BioRad, Hercules, CA, USA) was passively rehydrated overnight with 185 µl of IEF solution that contained 200 µg of solubilized mitochondrial enriched proteins. Isoelectric focusing was conducted at 30,000 V/h for a maximum of 5000 V using the Protean IEF cell (BioRad, Hercules, CA, USA). To prepare the sample for the second dimension electrophoresis, the IPG strip was first equilibrated for 20 min by rocking in a solution of 0.15 M BisTris, 100 mM HCl, 6 M urea, 2% (w/v) SDS, 20% (v/v) glycerol, 5 mM TBP, and 2.5% (w/v) iodoacetamide [37–40]. IPG strips were placed directly on top of the Criterion precast 8–16% gradient gel (BioRad, Hercules, CA, USA) and embedded with molten 1% (w/v) agarose. Gels were run in a dodeca cell at 25 V for 2 h and then at 85 V overnight at 5–8 °C until complete.

2.4.3. Gel staining, image acquisition and 2-D image analysis

After fixation in a solution of 10% (v/v) methanol and 7% (v/v) acetic acid, gels were stained in 100 ml of SYPRO Ruby fluorescent stain (Invitrogen, Carlsbad, CA, USA) overnight. Following staining, the gels were rinsed in double deionised water and destined for 30 min in a solution containing 10% (v/v) methanol and 7% (v/v) acetic acid to reduce the background fluorescence. The gels were immediately imaged using a Molecular Imager FX (Biorad, Hercules, CA, USA) and image analysis was performed by using PDQuest 1.0 2-D imaging software (BioRad, Hercules CA, USA).

2.4.4. Mass spectrometric protein identification

Protein spots were excised from the gel using a Proteome Works spot cutting robot (Bio-Rad, Hercules, CA, USA) and in-gel trypsin digested. The digested peptide was spotted onto a matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) plate in a solution containing 5 mg/ml α -cyano-4-hydroxycinnamic acid in 50% (v/v) ACN and 0.1% (v/v) trifluoroacetic acid. Mass spectra were recorded on a VOYAGER DE-STR mass spectrometer (Applied Biosystems, Foster City, CA, USA) equipped with a Nd:YAG 200 Hz laser operated in positive reflector mode.

Identification of proteins from primary sequence databases was achieved by Mascot search engine, protein score identification was set >60 and considered significant ($p < 0.05$).

2.4.5. Protein enrichment analysis

Predicted protein-protein interactions and functional enrichment analysis were performed by the web resource String v.11 [41]. The minimum required interaction score was set to high confidence (0.7), the p -value for protein-protein interaction (PPI) and false discovery rate for functional enrichment were inferior than 0.05. False discovery rate was shown as p -values corrected for multiple testing within each category using the Benjamini-Hochberg procedure.

2.5. Western blot analysis

Skeletal muscle specimens obtained from Group II were lysed in buffer containing 1% Triton and analyzed by Western blot as previously

described [29,36–38]. 20 µg protein samples were separated using SDS gel electrophoresis (Bio-Rad Laboratories Inc.) and electrotransferred to nitrocellulose membranes (Amersham Pharmacia Biotech Inc. CA, USA).

The membranes were probed with antibodies (Abcam, Cambridge, MA, USA) against mitofilin (Catalog Number: ab110329), ATP synthase subunit alpha (ATP5A, Catalog Number: ab14748), electron transfer flavoprotein subunit alpha (ETFA, Catalog Number: ab110316), pyruvate dehydrogenase protein x component (ODPX, Catalog Number: ab110334), cytochrome C oxidase subunit VIb (CX6B1, Catalog Number: ab110266), dihydrolipoamide dehydrogenase (DLDH, Catalog Number: ab186827), dihydrolipoamide S-succinyltransferase (DLST, Catalog Number: ab187699), short chain 3-hydroxyacyl-CoA dehydrogenase (HCDH, Catalog Number: ab154088), delta(3),delta(2)-enoyl-CoA isomerase (D3D2, Catalog Number: ab228544), enoyl-CoA Hydratase 1 (ECH1, Catalog Number: ab153720). Equal protein loading was confirmed by reblotting the membranes with monoclonal antibody against β -actin (Sigma-Aldrich, Milan, Italy). Blots were visualized using peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence detection, and band densities were quantified by densitometry. Skeletal muscle levels of the above indicated mitochondrial proteins were normalized to β -actin levels.

2.6. Statistical analysis

Variables that were not normally distributed, including triglycerides, fasting and 2-h post-load insulin concentrations, were natural log transformed for statistical analyses. Continuous variables are expressed as means \pm SD. Categorical variables were compared by χ^2 test. We used a general linear model with adjustment for age, gender and BMI to test pairwise differences in mitochondrial protein levels between NGT and type 2 diabetic groups. Relationships between mitochondrial protein levels and glucose homeostasis parameters were determined by Pearson's correlation coefficient (r). Wilcoxon's signed rank test was used to test differences in clinical parameters and mitochondrial protein expression between before and after treatment with placebo or pioglitazone. P value <0.05 was considered statistically significant. All analyses were performed using SPSS software programme Version 17.0 for Windows.

3. Results

3.1. Mitochondrial proteomic analysis in group I

A quantitative mitochondrial proteomic analysis was performed on mitochondrial enriched lysates obtained from skeletal muscle biopsies of 8 NGT and 8 type 2 diabetic subjects (Group I). The clinical characteristics of the study group I are shown in Suppl. Table 1. Fig. 1 shows representative two-dimensional protein profiles of skeletal muscle mitochondrial lysates of NGT and type 2 diabetic subjects.

Mitochondrial protein profiles were highly comparable between individuals with NGT and type 2 diabetes, indicating a low level of inter-individual and experimental variation that could confound data interpretation. By performing comparative visual and software-guided analyses of these two-dimensional protein profiles coupled to mass spectrometry, among several hundred spots we identified 76 mitochondrial proteins (Suppl. Table 2) among which 12 proteins were differentially expressed in skeletal muscle of subjects with type 2 diabetes compared to NGT individuals. The list of mitochondrial proteins differentially expressed and ratio of spot volumes between type 2 diabetic and NGT groups are shown in Table 1.

In particular, in skeletal muscle of type 2 diabetic subjects we found a downregulation of ATP5A, ETFA, CX6B1; all of these proteins are essential components of the mitochondrial electron transport chain. We also found a reduced abundance of ODPX, DLDH, DLST, which are enzymes involved in the Krebs cycle. Compared to NGT




Fig. 1. Representative images of two-dimensional protein profiles of skeletal muscle mitochondrial lysates of subjects with normal glucose tolerance (NGT) and type 2 diabetes mellitus (DM). ATP5A: ATP synthase alpha chain; ETFA: electron transfer flavoprotein alpha-subunit; CX6B1: cytochrome c oxidase subunit Vlb isoform 1; ODPX: pyruvate dehydrogenase protein X component; DLDH: dihydrolipoamide dehydrogenase; DLST: dihydrolipoamide S-succinyltransferase; HCDH: hydroxyacyl-coenzyme A dehydrogenase; D3D2: 3,2-trans-enoyl-CoA isomerase; ECH1: delta3,5-delta2,4-dienoyl-CoA isomerase; AK3: adenylate Kinase 3; CA3: carbonic anhydrase 3.

subjects, those with type 2 diabetes also displayed decreased skeletal muscle levels of mitofilin, a structural mitochondrial protein which plays a pivotal role in the maintenance of normal mitochondrial morphology and function [41]. Additionally, we found a higher abundance of enzymes involved in fatty acid oxidation including HCDH, D3D2 and ECH1 in skeletal muscle of subjects with type 2 diabetes compared to those with NGT.

3.2. Western blot analysis in group II

To confirm the results obtained by mitochondrial proteomic analysis, we assessed by Western blot the skeletal muscle levels of proteins involved in mitochondrial function, which were found to be differentially expressed in subjects with type 2 diabetes, in a separate larger study sample encompassing 48 individuals, 24 with NGT and 24 with type 2 diabetes (Group II). Anthropometric and biochemical parameters of the subjects in Group II are shown in Table 2. Type 2 diabetic subjects were older than NGT individuals, but matched for gender, BMI, and waist circumference. As expected, type 2 diabetic subjects exhibited higher levels of fasting and 2 h-post load plasma glucose, and glycated hemoglobin (HbA1c), increased plasma triglycerides, lower HDL concentrations, and reduced whole body insulin sensitivity.

After adjusting for age, gender and BMI, we found that protein levels of ATP5A, ETFA and CX6B1, key factors involved in mitochondrial ATP biosynthesis, were significantly reduced by $-30%$ ($P = 0.006$), $-50%$ ($P = 0.02$) and $-30%$ ($P = 0.03$), respectively, in the skeletal muscle of

Table 1

List of 2D gel electrophoresis-identified proteins differentially expressed in skeletal muscle of subjects with type 2 diabetes in comparison to NGT individuals.

	DM/NGT ratio	P
ATP synthase alpha chain (ATP5A)	0.46	0.03
Electron transfer flavoprotein alpha-subunit (ETFa)	0.78	0.04
Cytochrome c oxidase subunit Vlb isoform 1 (CX6B1)	0.71	0.03
Pyruvate dehydrogenase protein X component (ODPX)	0.55	0.02
Dihydrolipoamide dehydrogenase (DLDH)	0.80	0.03
Dihydrolipoamide S-succinyltransferase (DLST)	0.54	0.05
Mitofilin	0.59	0.02
Hydroxyacyl-coenzyme A dehydrogenase (HCDH)	1.33	0.05
3,2-trans-enoyl-CoA isomerase (D3D2)	1.27	0.05
Delta3,5-delta2,4-dienoyl-CoA isomerase (ECH1)	1.35	0.03
Adenylate Kinase 3 (AK3)	1.42	0.02
Carbonic anhydrase 3 (CA3)	1.81	0.02

List of spot proteins with different expression in subjects with type 2 diabetes mellitus (DM) in comparison to those with normal glucose tolerance (NGT). Ratio of spot volumes between DM and NGT is shown.

subjects with type 2 diabetes compared to NGT individuals (Fig. 2 A–D). Individuals affected by type 2 diabetes also displayed a decreased expression of mitofilin ($-30%$, $P = 0.01$) (Fig. 2 E) and reduced abundance of mitochondrial enzymes involved in oxidative metabolism including DLST ($-20%$, $P = 0.04$) and ODPX ($-26%$, $P \leq 0.05$) as compared to NGT subjects; no significant difference in DLDH protein levels was observed (Fig. 3 A–C). Additionally, we analyzed the protein expression of HCDH, ECH1 and D3D2, enzymes involved in fatty acid catabolism. After adjusting for age, gender and BMI we observed a significant increase in HCDH and ECH1 abundance ($+33%$, $P < 0.05$ and $+29%$, $P = 0.03$ respectively) in the skeletal muscle of subjects with type 2 diabetes compared to NGT individuals (Fig. 3 A, E–F); no significant difference between the two groups was observed for D3D2 protein levels (Fig. 3 A, G). Full blot images of the above indicated mitochondrial proteins are shown in Supplementary Figs. 1 and 2.

Additionally, we evaluated differences in skeletal muscle protein abundance of mitochondrial proteins between type 2 diabetes and

Table 2

Clinical characterization of individuals of study group II stratified according to glucose tolerance.

	NGT	DM	P
n (M/F)	12/12	14/10	0.56
Age (yrs)	39 ± 12	57 ± 7	≤0.001*
Anti-diabetic therapy		Diet 5 Met 13 Met+Sulf 6	
BMI (kg/m ²)	30 ± 7	32 ± 6	0.29
Waist circumference (cm)	97.4 ± 13	96.2 ± 17	0.98
Systolic blood pressure (mmHg)	125 ± 14	131 ± 12	0.25
Diastolic blood pressure (mmHg)	73 ± 11	73 ± 9	0.67
Fasting glucose (mg/dl)	94 ± 5	150 ± 37	≤0.001
2-h glucose (mg/dl)	118 ± 27	277 ± 51	≤0.001
HbA1c (%)	5.3 ± 0.3	7.5 ± 1.2	≤0.001
M-value (mg/kg·min)	7.7 ± 2.4	3.5 ± 1.5	≤0.001
Fasting insulin (mIU/ml)	4.06 ± 3.2	11.1 ± 11	0.13
2-h insulin (mIU/ml)	37 ± 19	40 ± 29	0.77
Total cholesterol (mg/dl)	174 ± 27	172 ± 36	0.42
HDL cholesterol (mg/dl)	46 ± 11	39 ± 8	0.02
LDL cholesterol (mg/dl)	104 ± 25	95 ± 33	0.37
Triglycerides (mg/dl)	103 ± 58	120 ± 96	0.03

Data are means ± SD. Triglycerides, fasting and 2-h post-load insulin were log transformed for statistical analysis, but values in the table represent back transformation to the original scale. Categorical variables were compared by χ^2 test. Comparisons between groups were performed using a general linear model. P values refer to results after analyses with adjustment for age, and gender. *P values refer to results after analyses with adjustment for gender. BMI: body mass index; HbA1c: glycated hemoglobin; HDL: high density lipoprotein; LDL: low density lipoprotein.




Fig. 2. Representative western blot images (A) and quantification of skeletal muscle ATP5A (B), ETF A (C), CX6B1 (D), and mitofilin (E) in subjects with type 2 diabetes (DM) and normal glucose tolerance (NGT). Band densities were quantified by densitometry. Skeletal muscle levels of the mitochondrial proteins were normalized to β -actin levels. *P* values reported above every graph refers to analyses adjusted for age, gender and BMI. NOD: normalized optical density.

NGT groups separately in men and women. We found that in women type 2 diabetes was associated with a downregulation of ATP5A (-35% , $P = 0.02$), ETF A (-40% , $P = 0.03$), CX6B1 (-22% , $P = 0.22$), DLST (-12% , $P = 0.11$), mitofilin (-30% , $P = 0.05$) and an upregulation of ECH1 ($+27\%$, $P = 0.07$). Protein levels of HCDH were not different between women with type 2 diabetes and NGT. In men, we observed that subjects with type 2 diabetes had reduced levels of ATP5A (-30% , $P = 0.01$), ETF A (-60% , $P = 0.01$), CX6B1 (-33% , $P = 0.02$), DLST (-22% , $P = 0.04$), mitofilin (-28% , $P = 0.01$) and an upregulation of HCDH ($+50\%$, $P = 0.04$) and ECH1 ($+30\%$, $P = 0.04$) in skeletal muscle as compared to NGT group.

Next, we evaluated the relationship between parameters of glucose homeostasis and skeletal muscle expression of mitochondrial proteins (Table 3). Univariate analysis revealed that protein levels of ATP5A, ETF A, CX6B1 and mitofilin were positively correlated with whole body insulin sensitivity and inversely with HbA1c, fasting and 2 h-post load plasma glucose levels. Skeletal muscle protein levels of ODPX and DLST were positively correlated with whole body insulin sensitivity and negatively correlated with HbA1c and 2 h-post load plasma glucose

levels. Additionally, we found that protein abundance of ECH1 and HCDH, enzymes implicated in fatty acid oxidation, was negatively correlated with whole body insulin sensitivity and positively correlated with 2 h-post load plasma glucose levels (Table 3).

3.3. Effect of pioglitazone treatment on skeletal muscle mitochondrial proteome

Next, we evaluated whether low-dose (15 mg/day) pioglitazone treatment could restore the content of mitochondrial proteins, which were found to be differentially expressed in skeletal muscle of subjects with type 2 diabetes compared to NGT individuals. Twenty subjects with type 2 diabetes were randomized to receive pioglitazone or placebo for 6 months. Clinical characterization at baseline and after pioglitazone or placebo treatment is shown in Supp. Table 2. Among subjects randomized to receive placebo six were treated with metformin alone, two with metformin plus sulfonylureas and one with diet alone at baseline. In the pioglitazone group, at baseline six subjects were treated with metformin alone, three with metformin plus sulfonylureas and two




Fig. 3. Representative western blot images (A) and quantification of skeletal muscle DLST (B), ODPX (C), DLDH (D), HCDH (E), ECH1 (F), D3D2 (G) in subjects with type 2 diabetes (DM) and normal glucose tolerance (NGT). Band densities were quantified by densitometry. Skeletal muscle levels of the mitochondrial proteins were normalized to β-actin levels. P values reported above every graph refers to analyses adjusted for age, gender and BMI. NOD: normalized optical density.

Table 3
Univariate correlations between mitochondrial protein levels in skeletal muscle and glucose homeostasis parameters.

	Whole body insulin sensitivity		Fasting plasma glucose		2 h-post load plasma glucose		HbA1c	
	r	P	r	P	r	P	r	P
ATP5A	0.60	≤0.0001	-0.44	0.002	-0.49	≤0.0001	-0.51	≤0.0001
ETFA	0.37	0.005	-0.40	0.003	-0.55	≤0.0001	-0.51	≤0.0001
CX6B1	0.41	0.007	-0.37	0.01	-0.33	0.03	-0.45	0.003
Mitofilin	0.34	0.02	-0.39	0.005	-0.37	0.01	-0.35	0.02
DLST	0.31	0.03	-0.21	0.15	-0.36	0.01	-0.29	0.05
ODPX	0.28	0.04	-0.16	0.23	-0.32	0.02	-0.35	0.01
DLDH	0.06	0.65	-0.05	0.69	-0.04	0.75	-0.07	0.61
HCDH	-0.27	0.05	0.19	0.16	0.29	0.03	0.26	0.09
ECH1	-0.38	0.03	0.27	0.13	0.32	0.05	0.27	0.15
D3D2	0.18	0.29	-0.28	0.09	-0.33	0.06	-0.34	0.06

with diet alone [29]. In both groups antidiabetic therapy was maintained stable during the study period and no other medications were added. The metabolic effects of pioglitazone treatment were described in a previously published study [29]. Briefly, diabetic subjects treated with pioglitazone for 6 months displayed lower levels of fasting and 2 h-post load glucose, HbA1c, triglycerides, total and low density lipoprotein (LDL) cholesterol, and improved whole body insulin sensitivity as compared to baseline (Suppl. Table 3).

Notably, after 6 months of treatment with low-dose pioglitazone skeletal muscle protein levels of ATP5A, ETFA and CX6B1 were significantly increased by +33% ($P\leq 0.05$), +60% ($P\leq 0.05$) and +33% ($P=0.01$), respectively, compared to baseline, whereas no change was observed in patients randomized to placebo (Fig. 4 A–D). Subjects treated with pioglitazone, but not those randomized to placebo, exhibited a 20% increase ($P\leq 0.05$) in the skeletal muscle abundance of mitofilin compared to baseline (Fig. 4 E). We observed an increase in skeletal muscle DLST levels in the pioglitazone-treated group compared to baseline, although it did not reach the threshold for statistical significance




Fig. 4. Representative western blot images (A) and quantification of skeletal muscle ATP5A, ETFA, CX6B1 and mitofilin at baseline (BAS) and after treatment with placebo (PLC) or pioglitazone (PIO) for 6 months (end of the study, EOS) in subjects with type 2 diabetes. Band densities were quantified by densitometry. Skeletal muscle levels of the mitochondrial proteins were normalized to β -actin levels. Comparison between baseline and after treatment data were performed by Wilcoxon's signed rank test. NOD: normalized optical density.

(+10%, $p = 0.08$) (Fig. 5 A–B). Protein levels of ODPX were not altered by either pioglitazone or placebo treatment (Fig. 5 A–C).

HCDH and ECH1 protein levels, which were upregulated in skeletal muscle of subjects with type 2 diabetes, were reduced by -10% and -15% , respectively ($P \leq 0.05$ for both) after pioglitazone treatment (Fig. 5 D–E).

3.4. Functional protein-protein interaction analysis

Fig. 6 shows the functional protein-protein interaction taking into consideration both the biochemical abnormalities in type 2 diabetes and the effect of low-dose pioglitazone treatment on skeletal muscle mitochondrial proteome. Subjects with type 2 diabetes exhibit reduced skeletal muscle levels of mitochondrial proteins involved in oxidative phosphorylation, oxidation-reduction processes, production of ATP and in the Krebs cycle (downregulation of CX6B1, ATP5A, ETFA, ODPX, mitofilin, DLDH and DLST). On the contrary, type 2 diabetes was characterized by the overexpression of proteins involved in metabolic process and especially on fatty acids beta-oxidation (upregulation of ECH1 and HCDH). Notably, the administration for 6 months of pioglitazone is

able to exert a positive effect on type 2 diabetes related abnormalities in mitochondrial proteome, especially restoring oxidative metabolism (upregulation of ATP5A, ETFA, mitofilin and CX6B1) and reducing protein levels of enzymes implicated in fatty acids catabolism (downregulation of HCDH and ECH1).

4. Discussion

Several mitochondria abnormalities have been described in skeletal muscle of subjects with type 2 diabetes [4–10].

However, the results of these studies were based on oligonucleotide microarray approaches or proteomic analysis by two-dimensional differential-gel electrophoresis performed on a small number of individuals [22–28] and did not examine whether these abnormalities could be improved by an intervention known to ameliorate skeletal muscle insulin resistance such as pioglitazone [29,31]. In order to identify abnormalities associated with mitochondrial dysfunction in skeletal muscle of type 2 diabetic subjects, we first compared the skeletal muscle mitochondrial proteomic profile in diabetic subjects with that of NGT individuals using 2D-gel electrophoresis coupled with mass




Fig. 5. Representative western blot images (A) and quantification of skeletal muscle DLST, ODPX, HCDH and ECH1 at baseline (BAS) and after treatment with placebo (PLC) or pioglitazone (PIO) for 6 months (end of the study, EOS) in subjects with type 2 diabetes. Band densities were quantified by densitometry. Skeletal muscle levels of the mitochondrial proteins were normalized to β -actin levels. Comparison between baseline and after treatment data were performed by Wilcoxon's signed rank test. NOD: normalized optical density.

spectrometry-based protein identification. Next, we confirmed our observations by performing Western blot analysis on skeletal muscle lysates obtained in a separate and larger study group.

Our results demonstrate that skeletal muscle abundance of mitochondrial enzymes involved in ATP production and oxidative metabolism is reduced in type 2 diabetic individuals as compared to those with NGT, even after adjustment for BMI, age and gender. Protein levels of key components of the mitochondrial electron transport chain (ATP5A, ETFA and CX6B1) and mitochondrial enzymes involved in Krebs cycle (DLST and ODPX) were significantly reduced in the skeletal muscle of subjects with type 2 diabetes. Levels of mitofilin, a protein anchored to the mitochondrial inner membrane, which has been shown to play a critical role in maintaining the mitochondrial structural and functional integrity [42], was also decreased in diabetic subjects. These results are in agreement with previous reports suggesting an association between type 2 diabetes and reduced electron transport chain and Krebs cycle activity and altered mitochondrial structural integrity in skeletal muscle [7–9,43]. Despite the gender related differences in pathogenic mechanisms of type 2 diabetes [44–46], we observed that the directional changes, as well as the magnitude of the

changes in mitochondrial protein levels were similar in males and females.

The reduced abundance of mitochondrial proteins involved in oxidative phosphorylation in type 2 diabetic subjects was associated with an increased expression of HCDH and ECH1, enzymes implicated in fatty acid oxidation. With regard to this, conflicting results have been published with studies demonstrating both decreased and increased fatty acid oxidative enzyme expression and/or activity in type 2 diabetic individuals [4,24,43,47,48]. Some studies have suggested that skeletal muscle fatty acid oxidation is reduced in type 2 diabetes and that the impairment in fat oxidation contributes to insulin resistance by promoting the accumulation of toxic intracellular lipid metabolites [24,48,49]. However, increasing evidence has suggested that both obesity and type 2 diabetes are associated with increased lipid oxidation, which is incomplete and not coupled to a higher rate of mitochondrial respiration [5,43,50]. Consistent with this proposed model, we found that individuals with type 2 diabetes exhibited increased skeletal muscle levels of enzymes involved in fatty acid catabolism, accompanied by reduced abundance of proteins involved in downstream metabolic pathways, such as the Krebs cycle and electron transport chain. The imbalance




Fig. 6. Functional protein-protein interaction in (A) healthy and (B) type 2 diabetes skeletal muscle mitochondrial proteome. The protein network is divided into clusters (color-coded) according to the protein biological process. In the figure are evidenced oxidation-reduction process (gene ontology, GO:0055114, green), fatty acid beta-oxidation (GO:0006635, lime), generation of precursor metabolites and energy (GO:0006091, pink), small molecule metabolic process (GO:0044281, red), and carboxylic acid catabolic process (GO:0019752, blue). The arrows indicate the modulation of the protein expression in type 2 diabetes (upregulated in teal and downregulated in light teal) and in type 2 diabetes after six months of low-dose pioglitazone (upregulated in orange and downregulated in light orange). The thickness of the grey lines between edges indicates the strength of data support. The minimum required interaction score was set to high confidence (>0.7), false discovery rate, and PPI enrichment p -value were in here inferior to 0.05.

between β -oxidation and Krebs cycle/electron transport chain activity may promote intracellular accumulation of incompletely metabolized lipids [15,16], resulting in an elevated concentration of intramitochondrial and cytoplasmic NADH [8]. A higher NADH/NAD ratio is known to impair pyruvate dehydrogenase, driving pyruvate to oxaloacetate and citrate [11,51]. Impaired citrate consumption in the Krebs cycle could lead to its accumulation in mitochondria and cytoplasm, where it is used as a precursor of acetyl-CoA, malonyl-CoA, and diacyl- and triacylglycerols [8,52]. Further, increased levels of NADH can inhibit the activity of the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase and, together with the accumulation of pyruvate, lead to accumulation of glycolytic intermediates. This would increase flux into the polyol, hexosamine, protein kinase C and advanced glycation end-product pathways, thereby worsening insulin resistance and glucose metabolism [11]. Consistent with this scenario, we found a close correlation between the abundance of several mitochondrial proteins involved in the Krebs cycle and electron chain transport versus insulin sensitivity and glucose control, including HbA1c and 2-h plasma glucose during OGTT. To the contrary, levels of enzymes involved in fatty acid oxidation, ECH1 and HCDH, were negatively associated with insulin sensitivity and positively correlated with 2-h plasma glucose levels.

In the present study we also evaluated the *in vivo* effect of low-dose pioglitazone on mitochondrial proteome profile. We found that the improvement in insulin sensitivity and glucose homeostasis in type 2 diabetic subjects treated with low-dose pioglitazone for 6 months was associated with a restored expression of the electron transport chain components ATP5A, CX6B1 and ETFA and a significant increase in the abundance of mitofilin. Moreover, the up-regulated skeletal muscle expression of ECH1 and HCDH in subjects with diabetes was decreased by pioglitazone treatment, indicating that pioglitazone improved the diabetes-related aberrant abundance of mitochondrial proteins. These results support previous evidence suggesting that pioglitazone improves skeletal muscle mitochondrial health by increasing the transcript

levels of genes involved in oxidative metabolism and reducing muscle β -oxidation capacity [30,32,53]. However, there are reports in which no effect of pioglitazone on muscle mitochondrial activity and its influence on *in-vivo* glucose metabolism was observed [54–55]. The difference between these previous results could be explained by differences in the patient population, *i.e.* nondiabetic subjects with the metabolic syndrome were studied by Yokata et al. [54], and differences in the study duration and dose of pioglitazone [54–55]. Further, in this previous study no increase in insulin-stimulated whole body glucose disposal was observed [54]. Therefore, one would not expect any change in mitochondrial function.

The present study has some strengths including the analysis of skeletal muscle mitochondrial proteome performed by 2D-gel electrophoresis and tandem-mass-spectrometry, the validation of the results obtained by 2D-gel based proteomic approach by Western blot analysis performed on a larger sample, detailed anthropometric and biochemical characterization including OGTT and clamp procedures to evaluate glucose homeostasis and whole body insulin sensitivity, assessment of mitochondrial protein abundance in skeletal muscle of type 2 diabetic individuals before and after treatment with pioglitazone or placebo.

However, there are some limitations of the present study. First, there was a difference in age between the diabetic and control groups. Although aging may affect expression and activity of mitochondrial enzymes [56], the observed differences in mitochondrial protein levels between the diabetic and the control groups were not affected by adjustment for age. Another limitation of this proteomic analysis is that we did not evaluate post-translational modifications of proteins as previously reported by others [26,27]. Aruda et al. have demonstrated differences in mitochondria-associated ER membranes in obese individuals, raising the possibility that structural mitochondrial alterations are present in obesity/T2DM [57]. Thus, a limitation of this study is that we did not examine whether structural alteration of mitochondrial proteins could account for some of the differences that we observed between T2DM and NGT subjects. Second, mitochondrial enzymatic activities

were not assessed in the skeletal muscle biopsies. Thus, it remains to be determined whether the altered abundance of proteins involved in oxidative metabolism found in diabetic subjects is translated to altered enzymatic activity of these proteins. Third, although there is a close relationship between altered levels of multiple skeletal muscle proteins and both insulin resistance and impaired glucose homeostasis, these do not prove causality.

5. Conclusion

In conclusion, our findings demonstrate that subjects with type 2 diabetes have reduced levels of mitochondrial proteins involved in oxidative phosphorylation and an increased abundance of enzymes involved in fatty acid catabolism in the skeletal muscle. Importantly, pioglitazone at low-dose is able to exert a positive effect on the abnormal mitochondrial protein profile in the skeletal muscle of subjects with type 2 diabetes.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.metabol.2020.154416>.

Authors contribution

TVF wrote and edited the manuscript, performed WB experiments and analyzed the data. AM, GD, AOC, MAG collected the data. AM and SK performed proteomic analysis. SK and RS contributed to WB analyses. MDC performed protein-protein interaction and functional analysis. DT, MAG, MLH, GS contributed to the discussion and to the interpretation of the data. RAD reviewed and corrected the manuscript. FF conceived the study, interpreted data and reviewed the manuscript. FF is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Fundings

This work was supported by Takeda with an investigator initiated study and by start-up funding from the University of Texas Health Science Center, San Antonio, TX, USA to FF, and by NIH grant DK24092-38 to RAD. T.V.F. was supported in part by a fellowship from Fo.Ri.SID, Italy. A.M. was supported by a Minority Postdoctoral Fellowship from the American Diabetes Association awarded to R.A.D.

CRedit authorship contribution statement

Teresa Vanessa Fiorentino: Conceptualization, Methodology, Investigation, Formal analysis, Writing - review & editing. **Adriana Monroy:** Writing - original draft, Investigation, Resources. **Subash Kamath:** Writing - original draft, Investigation, Resources. **Rosa Sotero:** Investigation. **Michele Dei Cas:** Formal analysis, Writing - review & editing. **Giuseppe Daniele:** Investigation, Data curation. **Alberto O. Chavez:** Investigation. **Muhammad Abdul-Ghani:** Investigation, Data curation. **Marta Letizia Hribal:** Visualization, Writing - review & editing. **Giorgio Sesti:** Visualization, Writing - review & editing. **Devjit Tripathy:** Visualization, Writing - review & editing. **Ralph A. DeFronzo:** Visualization, Supervision, Project administration, Writing - review & editing, Funding acquisition. **Franco Folli:** Conceptualization, Visualization, Supervision, Project administration, Writing - review & editing, Funding acquisition.

Declaration of competing interest

The authors have no conflict of interest.

Acknowledgment

We thank the nursing staff of the Diabetes Research Unit of the Bartter Clinical Research Unit of the South Texas Veterans Health Care

system for their expert assistance in performing the studies, and Prof Rita Clara Paroni, Department of Health Science, University of Milan, for her help in the revision of the manuscript.

References

- [1] DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes, and atherosclerosis: the missing links. The Claude Bernard lecture. *Diabetologia*. 2010;53:1270–87.
- [2] DeFronzo R, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. *Nat Rev Dis Primers*. 2015;1:15019.
- [3] Abdul-Ghani MA, Muller FL, Liu Y, Chavez AO, Balas B, Zuo P, et al. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. *Am J Physiol*. 2008;295:E678–85.
- [4] Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. *Cell Metab*. 2008;7:45–56.
- [5] Befroy DE, Petersen KF, Dufour S, Mason GF, de Graaf RA, Rothman DL, et al. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. *Diabetes*. 2007;56:1376–81.
- [6] Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. *Circ Res*. 2008;102:401–14.
- [7] Mogensen M, Sahlin K, Fernström M, Glintborg D, Vind BF, Beck-Nielsen H, et al. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. *Diabetes*. 2007;56:1592–9.
- [8] Ritov VB, Menshikova EV, Azuma K, Wood R, Toledo FG, Goodpaster BH, et al. Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. *Am J Physiol Endocrinol Metab*. 2010;298:E49–58.
- [9] Abdul-Ghani MA, DeFronzo RA. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. *Curr Diab Rep*. 2008;8:173–8.
- [10] Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. *Diabetes*. 2000;49:677–83.
- [11] Fiorentino TV, Priolella A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. *Curr Pharm Des*. 2013;19:5695–703.
- [12] Simoneau JA, Kelley DE. Altered skeletal muscle glycolytic and oxidative capacities contribute to insulin resistance in NIDDM. *J Appl Physiol*. 1997;83:166–71.
- [13] Yu HY, Inoguchi T, Kakimoto M, Nakashima N, Imanuma M, Hashimoto T, et al. Saturated non-esterified fatty acids stimulate de novo diacylglycerol synthesis and protein kinase C activity in cultured aortic smooth muscle cells. *Diabetologia*. 2001;44:614–20.
- [14] Sriwijitkamol A, Christ-Roberts C, Berria R, Eagen P, Pratipanawatr T, DeFronzo RA, et al. Reduced skeletal muscle inhibitor of kappaB content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. *Diabetes*. 2006;55:760–7.
- [15] Tantiwong P, Shanmugasundaram K, Monroy A, Ghosh S, Li M, DeFronzo RA, et al. NF-κB activity in muscle from obese and type 2 diabetic subjects under basal and exercise-stimulated conditions. *Am J Physiol Endocrinol Metab*. 2010;299:E794–801.
- [16] Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, et al. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. *Diabetes*. 2008;57:2595–602.
- [17] Kang J, Heart E, Sung CK. Effects of cellular ATP depletion on glucose transport and insulin signaling in 3T3-L1 adipocytes. *Am J Physiol Endocrinol Metab*. 2001;280:E428–35.
- [18] Hresko R, Heimberg H, Chi M, Mueckler MM. Glucosamine-induced insulin resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP. *J Biol Chem*. 1998;273:20658–68.
- [19] Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA, Sowers JR. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. *Am J Physiol Regul Integr Comp Physiol*. 2008;294:R673–80.
- [20] Nishikawa T, Edelstein D, Du X-L, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondria superoxide production blocks three pathways of hyperglycemic damage. *Nature*. 2000;404:787–90.
- [21] Bonnard C, Durand A, Peyrol S, Chanseume E, Chauvin MA, Morio B, et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. *J Clin Invest*. 2008;118:789–800.
- [22] Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS. Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. *Diabetes*. 2002;51:1913–20.
- [23] Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet*. 2003;34:267–73.
- [24] Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. *Proc Natl Acad Sci U S A*. 2003;100:8466–71.
- [25] Hwang H, Bowen BP, Lefort N, Flynn CR, De Filippis EA, Roberts C, et al. Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes. *Diabetes*. 2010;59:33–42.
- [26] Højlund K, Wrzesinski K, Larsen PM, Fey SJ, Roepstorff P, Handberg A, et al. Proteome analysis reveals phosphorylation of ATP synthase beta-subunit in human skeletal muscle and proteins with potential roles in type 2 diabetes. *J Biol Chem*. 2003;278:10436–42.
- [27] Giebelstein J, Poschmann G, Højlund K, Schechinger W, Dietrich JW, Levin K, et al. The proteomic signature of insulin-resistant human skeletal muscle reveals increased glycolytic and decreased mitochondrial enzymes. *Diabetologia*. 2012;55:1114–27.

- [28] Sehyun C, Su-Jin K, Young Do K, Jung Hwa L, Hokeun K, Byung Yong A, et al. A mitochondrial proteome profile indicative of type 2 diabetes mellitus in skeletal muscles. *Exp Mol Med*. 2018;50:129.
- [29] Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, et al. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. *Diabetologia*. 2013;56:2153–63.
- [30] Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. *Diabetes*. 2005;54:1392–9.
- [31] Eldor R, DeFronzo RA, Abdul-Ghani M. In-vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. *Diabetes Care*. 2013;36(Suppl. 2):S162–74.
- [32] Coletta DK, Sriwijitkamol A, Wajsborg E, Tantiwong P, Li M, Prentki M, et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. *Diabetologia*. 2009;52:723–32.
- [33] Pagel-Langenickel I, Bao J, Joseph JJ, Schwartz DR, Mantell BS, Xu X, et al. PGC-1 α integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle. *J Biol Chem*. 2008;283:22464–72.
- [34] Skov V, Glinborg D, Knudsen S, Tan Q, Jensen T, Kruse TA, et al. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. *PLoS One*. 2008;3:e2466.
- [35] Ades PA, Savage PD, Toth MJ, Harvey-Berino J, Schneider DJ, Bunn JY, et al. High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. *Circulation*. 2009;119:2671–8.
- [36] Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, et al. Impaired regulation of the TNF- α converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. *Diabetologia*. 2009;52:2169–81.
- [37] Monroy A, Carroll C, Chavez AO, Barrentine A, Abdul-Ghani MA, Tripathy D, et al. Mitochondrial proteomics of human type 2 diabetic skeletal muscle reveals downregulation of selected respiratory chain components. *Diabetes*. 2008;57:A429.
- [38] Fiorentino TV, Monroy A, Kamath S, Carroll C, Hakala K, Sotero R, et al. Pioglitazone treatment reverts diabetes-related abnormalities in mitochondrial proteomic profile of skeletal muscle. *Diabetologia*. 2018;61:S113.
- [39] Folli F, Guzzi V, Perego L, Coletta DK, Finzi G, Placidi C, et al. Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. *PLoS One*. 2010;5(3):e9923.
- [40] Weintraub S, Carroll CA, Kamath S, Monroy A, Chavez-Velasquez AO, DeFronzo R, et al. Exploration of the human muscle proteome in diabetes. *Mol Cell Proteomics*. 2007;6(8 suppl 1):S67.
- [41] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res*. 2019;47(D1):D607–13.
- [42] John GB, Shang Y, Li L, Renken C, Mannella CA, Selker JM, et al. The mitochondrial inner membrane protein mitofilin controls cristae morphology. *Mol Biol Cell*. 2005;16:1543–54.
- [43] Yechoor VK, Patti ME, Saccone R, Kahn CR. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. *Proc Natl Acad Sci U S A*. 2002;99:10587–92.
- [44] Mauvais-Jarvis F. Gender differences in glucose homeostasis and diabetes. *Physiol Behav*. 2018;187:20–3.
- [45] Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. *Endocr Rev*. 2017;38:173–88.
- [46] Calvo SE, Mootha VK. The mitochondrial proteome and human disease. *Annu Rev Genomics Hum Genet*. 2010;11:25–44.
- [47] Mullen E, Ohlendieck K. Proteomic profiling of non-obese type 2 diabetic skeletal muscle. *Int J Mol Med*. 2010;25:445–58.
- [48] McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. *Diabetes*. 2002;51:7–18.
- [49] Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I κ B α . *Diabetes*. 2002;51:2005–11.
- [50] Koves TR, Li P, An J, Akimoto T, Slentz D, Ilkayeva O, et al. Peroxisome proliferator-activated receptor- γ co-activator 1 α -mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. *J Biol Chem*. 2005;280:33588–98.
- [51] Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Santini E, Ferrannini E, et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2006;91:806–12.
- [52] Saha AK, Vavvas D, Kurowski TG, Apazidis A, Witters LA, Shafir E, et al. Malonyl-CoA regulation in skeletal muscle: its link to cell citrate and the glucose-fatty acid cycle. *Am J Physiol*. 1997;272:E641–8.
- [53] Wessels B, Ciapaite J, van den Broek NM, Houten SM, Nicolay K, Prompers JJ. Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes. *Diabetes Obes Metab*. 2015;17:52–60.
- [54] Yokota T, Kinugawa S, Hirabayashi K, Suga T, Takada S, Omokawa M, et al. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. *J Diabetes Investig*. 2017;8:535–41.
- [55] Bajpeyi S, Pasarica M, Conley KE, Newcomer BR, Jubrias SA, Gamboa C, et al. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function. *Metabolism*. 2017;69:24–32.
- [56] Gelfi C, Viganò A, Ripamonti M, Pontoglio A, Begum S, Pellegrino MA, et al. The human muscle proteome in aging. *J Proteome Res*. 2006;5:1344–53.
- [57] Arruda AP, Pers BM, Parlakgöl G, Güney E, Inouye K, Hotamisligil GS. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. *Nat Med*. 2014;20:1427–35.